Why the pharma supply chain is about to change

A pharma company is taking on the big pharma business by integrating logistics, warehousing, and marketing into the supply chain of the drug supply chain, a startup that’s now trying to build a global supply chain for the world’s biggest pharma companies.

The company is called Liox, and it plans to use a blockchain to connect the supply chains of the biggest drugmakers in the world.

Liox aims to be the largest supply chain solution in the pharmas business by 2021, according to CEO André Lioux.

The pharma industry is growing at a rate of more than 1 million new jobs each year, and there are currently over 8,000 global drugmakers and about 40,000 regional and regional suppliers that supply their drugs to the world, according a 2016 study from McKinsey & Co. The global pharmaceutical industry has about 4.6 trillion dollars in annual revenue.

To make the transition to a blockchain-based supply chain that’s both decentralized and decentralized for the entire industry, Lioix will use a “tokenized, distributed supply chain” called LIOX, according its mission statement.LIOX is intended to be a global, decentralized supply chain to make sure the pharms drug supply and delivery systems are as decentralized as possible.

LioX will be a decentralized, distributed, decentralized-by-token, decentralized platform that will enable the global supply and distribution of pharmaceutical products.

Liolx uses blockchain technology to enable the distribution of medicines across a global network, using the blockchain for allocating scarce supply and distributing medicines as fast as possible, said the company’s founder and CEO, AndréLioux, in a recent interview with CoinDesk.

Licox plans to be able to distribute medicine worldwide, including to all 50 states of the US and Canada, and other countries.

This will require more supply chains, more logistics, more manufacturing facilities, and more manufacturing capacity.

LiotX, the company that has been developing a blockchain for the pharmaceutical industry, is also taking on a blockchain solution to solve the supply-chain issues of the global pharma economy, according the company.

LiotX is working with pharma and pharmaceutical companies to build their own blockchain-enabled supply chain solutions that will integrate logistics, supply chain management, and logistics analytics into their supply chain.

Lialx, which is working to be an early investor in the global drug supply, said that it has already invested in about 1,000 pharma-related companies in more than 50 countries and territories.

This includes a total of 10 global drug companies, including several major pharma suppliers.

The company has already received funding from a number of investors, including a large amount from the United States.

Liopx is a blockchain startup working on a platform that allows companies to use blockchain technology in order to create supply chains that are more decentralized and transparent.

The platform is a distributed ledger of data.

This data is stored in a blockchain that has no central server, and is decentralized and peer-to-peer.

Liopx also works with pharmas companies to develop supply chain protocols that are based on Lioxes platform.

Lolx is now working with several pharma drugmakers, including Novartis, Pfizer, Bristol-Myers Squibb, Pfaff, and Valeant, and they are collaborating to provide their products to the global pharmaceutical supply chain through the Lioxp platform.

Liolx is working on other projects, including providing blockchain solutions for logistics logistics, logistics management, supply-chains management, blockchain applications, and a drug delivery platform.

“LioX aims to create a global decentralized supply-channel that is as decentralized and decentralised as possible,” Lioxx founder André says.

“By integrating logistics management and logistics software, LiolX aims not only to help pharmas supply-changers and pharmaceutical manufacturers, but also to make global supply chains safer and more transparent for all.

We are excited to partner with these leading companies, who share our vision of decentralized supply chains.”

In 2017, Lios, a pharma startup, raised $1 million in funding from the French company Antimony Ventures and others.

In 2017, the Paris-based startup also raised $3 million from the German company Mediapart.

In 2018, LiopX partnered with Liolix to create the global Liolox network.

Liaiox is currently working with Lioxtix to bring the blockchain-driven logistics platform to Europe.

The blockchain technology is designed to enable decentralized, decentralized drug supply chains.

Liu Xu, an associate professor at Harvard Business School and a pharmas expert, said: “This is a very interesting project that will help to solve problems in the supply side of the pharmaco industry.”

Lioxx has already developed a blockchain application to handle logistics for its customers, and will be working with pharmaceutical companies on a decentralized supply management system for the global market.

Lios blockchain-oriented